$441.9
Live
Elevance Health Inc is a healthcare company that leverages data analytics and artificial intelligence to improve patient outcomes and reduce healthcare costs.
Revenue is up for the last 3 quarters, 39.92B → 43.67B (in $), with an average increase of 4.4% per quarter
Netprofit is down for the last 2 quarters, 1.98B → 1.85B (in $), with an average decrease of 6.7% per quarter
In the last 1 year, The Cigna Corp has given 3.5% return, outperforming this stock by 5.6%
In the last 3 years, The Cigna Corp has given 76.7% return, outperforming this stock by 4.5%
0.23%
Downside
Day's Volatility :1.12%
Upside
0.89%
7.08%
Downside
52 Weeks Volatility :24.36%
Upside
18.6%
Period | Elevance Health, Inc | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 1.63% | -1.3% | -2.2% |
6 Months | -1.95% | 1.8% | 6.8% |
1 Year | -2.08% | 5.6% | 18.1% |
3 Years | 72.17% | 24.9% | 28.9% |
Market Capitalization | 104.8B |
Book Value | $161.98 |
Dividend Share | 5.52 |
Dividend Yield | 1.32% |
Earnings Per Share (EPS) | 26.84 |
PE Ratio | 16.57 |
PEG Ratio | 1.38 |
Wall Street Target Price | 569.78 |
Profit Margin | 3.89% |
Operating Margin TTM | 5.67% |
Return On Assets TTM | 5.59% |
Return On Equity TTM | 17.43% |
Revenue TTM | 165.7B |
Revenue Per Share TTM | 696.29 |
Quarterly Revenue Growth YOY | 13.0% |
Gross Profit TTM | 40.1B |
EBITDA | 10.6B |
Diluted Eps TTM | 26.84 |
Quarterly Earnings Growth YOY | 0.16 |
EPS Estimate Current Year | 32.93 |
EPS Estimate Next Year | 37.01 |
EPS Estimate Current Quarter | 8.8 |
EPS Estimate Next Quarter | 8.43 |
What analysts predicted
Upside of 28.94%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 90.0B | ↑ 6.1% |
Net Income | 3.8B | ↑ 55.59% |
Net Profit Margin | 4.27% | ↑ 1.36% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 92.1B | ↑ 2.29% |
Net Income | 3.8B | ↓ 2.41% |
Net Profit Margin | 4.07% | ↓ 0.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 104.2B | ↑ 13.15% |
Net Income | 4.8B | ↑ 28.19% |
Net Profit Margin | 4.61% | ↑ 0.54% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 121.9B | ↑ 16.94% |
Net Income | 4.6B | ↓ 4.89% |
Net Profit Margin | 3.75% | ↓ 0.86% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 138.6B | ↑ 13.76% |
Net Income | 6.1B | ↑ 33.51% |
Net Profit Margin | 4.4% | ↑ 0.65% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 156.6B | ↑ 12.95% |
Net Income | 6.0B | ↓ 1.29% |
Net Profit Margin | 3.85% | ↓ 0.55% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.1B | ↑ 4.14% |
Net Income | 1.8B | ↑ 58.75% |
Net Profit Margin | 4.74% | ↑ 1.63% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 38.6B | ↑ 1.41% |
Net Income | 1.7B | ↓ 8.42% |
Net Profit Margin | 4.28% | ↓ 0.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 39.9B | ↑ 3.38% |
Net Income | 1.6B | ↓ 2.42% |
Net Profit Margin | 4.04% | ↓ 0.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 39.9B | ↓ 0.03% |
Net Income | 949.0M | ↓ 41.17% |
Net Profit Margin | 2.38% | ↓ 1.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 42.2B | ↑ 5.62% |
Net Income | 2.0B | ↑ 109.59% |
Net Profit Margin | 4.72% | ↑ 2.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.7B | ↑ 3.56% |
Net Income | 1.9B | ↓ 6.69% |
Net Profit Margin | 4.25% | ↓ 0.47% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 70.5B | ↑ 8.38% |
Total Liabilities | 44.0B | ↑ 10.14% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 71.6B | ↑ 1.46% |
Total Liabilities | 43.0B | ↓ 2.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 77.5B | ↑ 8.22% |
Total Liabilities | 45.7B | ↑ 6.26% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 86.6B | ↑ 11.83% |
Total Liabilities | 53.4B | ↑ 16.82% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 97.5B | ↑ 12.52% |
Total Liabilities | 61.3B | ↑ 14.82% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 102.8B | ↑ 5.45% |
Total Liabilities | 66.5B | ↑ 8.37% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 100.5B | ↑ 3.1% |
Total Liabilities | 64.5B | ↑ 5.09% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 100.9B | ↑ 0.39% |
Total Liabilities | 65.0B | ↑ 0.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 103.0B | ↑ 2.13% |
Total Liabilities | 67.0B | ↑ 3.03% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 102.8B | ↓ 0.25% |
Total Liabilities | 66.5B | ↓ 0.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 109.0B | ↑ 6.1% |
Total Liabilities | 71.6B | ↑ 7.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 109.2B | ↑ 0.12% |
Total Liabilities | 70.9B | ↓ 1.01% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.2B | ↑ 30.59% |
Investing Cash Flow | -5.1B | ↑ 888.99% |
Financing Cash Flow | 426.9M | ↓ 158.25% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.8B | ↓ 8.55% |
Investing Cash Flow | -1.3B | ↓ 75.23% |
Financing Cash Flow | -2.2B | ↓ 624.95% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.1B | ↑ 58.37% |
Investing Cash Flow | -2.8B | ↑ 121.76% |
Financing Cash Flow | -2.3B | ↑ 1.12% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.7B | ↑ 76.34% |
Investing Cash Flow | -7.3B | ↑ 162.32% |
Financing Cash Flow | -2.6B | ↑ 13.28% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↓ 21.74% |
Investing Cash Flow | -9.6B | ↑ 31.59% |
Financing Cash Flow | 423.0M | ↓ 116.48% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↑ 0.42% |
Investing Cash Flow | -4.6B | ↓ 52.69% |
Financing Cash Flow | -1.3B | ↓ 411.58% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↑ 51.97% |
Investing Cash Flow | -1.6B | ↑ 63.35% |
Financing Cash Flow | 322.0M | ↓ 124.49% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↓ 3.5% |
Investing Cash Flow | -2.0B | ↑ 28.26% |
Financing Cash Flow | -127.0M | ↓ 139.44% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.9B | ↑ 100.82% |
Investing Cash Flow | -1.2B | ↓ 38.39% |
Financing Cash Flow | -1.3B | ↑ 888.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↑ 70.57% |
Investing Cash Flow | -4.6B | ↑ 265.68% |
Financing Cash Flow | -1.3B | ↑ 5.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.5B | ↓ 22.98% |
Investing Cash Flow | -3.2B | ↓ 30.18% |
Financing Cash Flow | -531.0M | ↓ 59.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↑ 30.14% |
Investing Cash Flow | -3.9B | ↑ 21.11% |
Financing Cash Flow | -2.0B | ↑ 269.3% |
Sell
Neutral
Buy
Elevance Health, Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Elevance Health, Inc | -2.3% | -1.95% | -2.08% | 72.17% | 61.94% |
![]() The Cigna Corp | 3.08% | 14.29% | 3.48% | 76.69% | 37.64% |
![]() Unitedhealth Group Incorporated | 3.5% | 9.33% | 0.25% | 67.71% | 89.56% |
![]() Cvs Health Corporation | 4.32% | -5.48% | -27.79% | 21.71% | -11.91% |
![]() Humana Inc. | 2.89% | 1.95% | 0.85% | 23.34% | 46.33% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Elevance Health, Inc | 16.57 | 16.57 | 1.38 | 32.93 | 0.17 | 0.06 | 0.01 | 161.98 |
![]() The Cigna Corp | 13.29 | 13.29 | 1.22 | 24.81 | 0.15 | 0.03 | 0.02 | 153.69 |
![]() Unitedhealth Group Incorporated | 22.85 | 22.85 | 1.66 | 24.85 | 0.25 | 0.07 | 0.01 | 88.84 |
![]() Cvs Health Corporation | 32.72 | 32.72 | 1.36 | 8.59 | 0.04 | 0.04 | 0.03 | 56.73 |
![]() Humana Inc. | 18.37 | 18.37 | 1.28 | 28.3 | 0.21 | 0.06 | 0.01 | 135.86 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Elevance Health, Inc | Buy | $104.8B | 61.94% | 16.57 | 3.89% |
![]() The Cigna Corp | Buy | $85.9B | 37.64% | 13.29 | 3.57% |
![]() Unitedhealth Group Incorporated | Buy | $472.5B | 89.56% | 22.85 | 6.06% |
![]() Cvs Health Corporation | Buy | $91.9B | -11.91% | 32.72 | 0.83% |
![]() Humana Inc. | Buy | $61.2B | 46.33% | 18.37 | 3.42% |
Vanguard Group Inc
BlackRock Inc
T. Rowe Price Associates, Inc.
State Street Corporation
Wellington Management Company LLP
Capital Research & Mgmt Co - Division 3
In the quarter ending March,2023. Elevance Health, Inc has declared dividend of $1.48
Read MoreElevance Health, Inc. is an American health insurance provider. Prior to June 2022, Elevance Health was named Anthem, Inc.
Organization | Elevance Health, Inc |
Employees | 102300 |
CEO | Ms. Gail Koziara Boudreaux |
Industry | Healthcare |
Fresenius Medical Care Ag & Co. Kgaa
$441.90
-1.2%
Zimmer Biomet Holdings, Inc.
$441.90
-1.2%
Edwards Lifesciences Corp.
$441.90
-1.2%
Iqvia Holdings Inc.
$441.90
-1.2%
Biogen Inc.
$441.90
-1.2%
United Therapeutics Corporation
$441.90
-1.2%
Horizon Therapeutics Public Ltd Co
$441.90
-1.2%
The Cigna Corp
$441.90
-1.2%
Biomarin Pharmaceutical Inc.
$441.90
-1.2%